NASDAQ: OACCOaktree Acquisition Corp III Life Sciences Stock
$10.10+0.03 (+0.3%)
Updated Apr 23, 2025
OACC Price
$10.10
Fair Value Price
N/A
Market Cap
$248.29M
52 Week Low
$9.95
52 Week High
$10.85
P/E
84.17x
P/B
-40.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$1.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.28
Operating Cash Flow
-$90k
Beta
0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OACC Overview
Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OACC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
OACC
Ranked#1 of 18
Ranked#1 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.09 | C | |
| $10.11 | C | |
| $9.87 | C |
Be the first to know about important OACC news, forecast changes, insider trades & much more!
OACC News
Overview
Due Diligence Score
–
Industry Average (11)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OACC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OACC is poor value based on its earnings relative to its share price (84.17x), compared to the US market average (26.95x)
P/E vs Market Valuation
OACC is good value based on its earnings relative to its share price (84.17x), compared to the US Shell Companies industry average (-26.39x)
P/E vs Industry Valuation
OACC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OACC due diligence checks available for Premium users.
Valuation
OACC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
84.17x
Industry
-26.39x
Market
26.95x
OACC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OACC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
OACC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-40.87x
Industry
-52.68x
OACC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
OACC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$195.3M
Liabilities
$7.7M
Debt to equity
-1.28
OACC's short-term assets ($1.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OACC's long-term liabilities ($7.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OACC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OACC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
OACC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OACC vs Shell Company Stocks
Oaktree Acquisition III Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.